Illumina (NASDAQ:ILMN) Stock Gets Price Target Cut from JPMorgan Chase & Co.

Illumina (NASDAQ:ILMN) had its price target lowered by JPMorgan Chase & Co. from $320.00 to $300.00 in a report published on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the life sciences company’s stock.

Several other research analysts also recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, October 19th. Royal Bank Of Canada upped their target price on Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Finally, Leerink Partners increased their target price on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $238.53.

Illumina Price Performance

Illumina stock opened at $235.99 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The company has a market cap of $35.63 billion, a P/E ratio of 40.62, a price-to-earnings-growth ratio of 3.30 and a beta of 1.46. Illumina has a one year low of $106.12 and a one year high of $309.35. The business has a fifty day moving average of $249.30 and a two-hundred day moving average of $176.18.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the previous year, the company posted $1.34 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, analysts predict that Illumina will post 5.43 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 2,061,235 shares of company stock worth $436,356,102. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Illumina during the second quarter worth approximately $3,374,423,000. WCM Investment Management LLC raised its holdings in Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA purchased a new stake in shares of Illumina in the second quarter worth $617,981,000. Janus Henderson Group PLC raised its stake in shares of Illumina by 1.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after acquiring an additional 29,094 shares during the period. Finally, Southpoint Capital Advisors LP lifted its position in shares of Illumina by 20.0% during the first quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock valued at $258,846,000 after buying an additional 349,536 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.